IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy
Historically, senescence has been considered a safe program in response to multiple stresses in which cells undergo irreversible growth arrest. This process is characterized by morphological and metabolic changes, heterochromatin formation, and secretion of inflammatory components, known as senescen...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Cell and Developmental Biology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2022.1083743/full |
| _version_ | 1828066547955924992 |
|---|---|
| author | Donatella Romaniello Donatella Romaniello Valerio Gelfo Valerio Gelfo Federica Pagano Michela Sgarzi Alessandra Morselli Cinzia Girone Daria Maria Filippini Daria Maria Filippini Gabriele D’Uva Gabriele D’Uva Gabriele D’Uva Mattia Lauriola Mattia Lauriola |
| author_facet | Donatella Romaniello Donatella Romaniello Valerio Gelfo Valerio Gelfo Federica Pagano Michela Sgarzi Alessandra Morselli Cinzia Girone Daria Maria Filippini Daria Maria Filippini Gabriele D’Uva Gabriele D’Uva Gabriele D’Uva Mattia Lauriola Mattia Lauriola |
| author_sort | Donatella Romaniello |
| collection | DOAJ |
| description | Historically, senescence has been considered a safe program in response to multiple stresses in which cells undergo irreversible growth arrest. This process is characterized by morphological and metabolic changes, heterochromatin formation, and secretion of inflammatory components, known as senescence-associated secretory phenotype (SASP). However, recent reports demonstrated that anti-cancer therapy itself can stimulate a senescence response in tumor cells, the so-called therapy-induced senescence (TIS), which may represent a temporary bypass pathway that promotes drug resistance. In this context, several studies have shown that EGFR blockage, by TKIs or moAbs, promotes TIS by increasing IL-1 cytokine production, thus pushing cells into a “pseudo-senescent” state. Today, senotherapeutic agents are emerging as a potential strategy in cancer treatment thanks to their dual role in annihilating senescent cells and simultaneously preventing their awakening into a resistant and aggressive form. Here, we summarize classic and recent findings about the cellular processes driving senescence and SASP, and we provide a state-of-the-art of the anti-cancer strategies available so far that exploits the activation and/or blockade of senescence-based mechanisms. |
| first_indexed | 2024-04-10T23:32:22Z |
| format | Article |
| id | doaj.art-f75c4facecf448f7af8a2eb3226c69b3 |
| institution | Directory Open Access Journal |
| issn | 2296-634X |
| language | English |
| last_indexed | 2024-04-10T23:32:22Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cell and Developmental Biology |
| spelling | doaj.art-f75c4facecf448f7af8a2eb3226c69b32023-01-12T05:45:00ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2023-01-011010.3389/fcell.2022.10837431083743IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapyDonatella Romaniello0Donatella Romaniello1Valerio Gelfo2Valerio Gelfo3Federica Pagano4Michela Sgarzi5Alessandra Morselli6Cinzia Girone7Daria Maria Filippini8Daria Maria Filippini9Gabriele D’Uva10Gabriele D’Uva11Gabriele D’Uva12Mattia Lauriola13Mattia Lauriola14Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, ItalyCentre for Applied Biomedical Research (CRBA), Bologna University Hospital Authority St. Orsola -Malpighi Polyclinic, Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, ItalyCentre for Applied Biomedical Research (CRBA), Bologna University Hospital Authority St. Orsola -Malpighi Polyclinic, Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, ItalyDivision of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, ItalyCentre for Applied Biomedical Research (CRBA), Bologna University Hospital Authority St. Orsola -Malpighi Polyclinic, Bologna, ItalyNational Laboratory of Molecular Biology and Stem Cell Engineering, National Institute of Biostructures and Biosystems (INBB), Bologna, ItalyDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, ItalyCentre for Applied Biomedical Research (CRBA), Bologna University Hospital Authority St. Orsola -Malpighi Polyclinic, Bologna, ItalyHistorically, senescence has been considered a safe program in response to multiple stresses in which cells undergo irreversible growth arrest. This process is characterized by morphological and metabolic changes, heterochromatin formation, and secretion of inflammatory components, known as senescence-associated secretory phenotype (SASP). However, recent reports demonstrated that anti-cancer therapy itself can stimulate a senescence response in tumor cells, the so-called therapy-induced senescence (TIS), which may represent a temporary bypass pathway that promotes drug resistance. In this context, several studies have shown that EGFR blockage, by TKIs or moAbs, promotes TIS by increasing IL-1 cytokine production, thus pushing cells into a “pseudo-senescent” state. Today, senotherapeutic agents are emerging as a potential strategy in cancer treatment thanks to their dual role in annihilating senescent cells and simultaneously preventing their awakening into a resistant and aggressive form. Here, we summarize classic and recent findings about the cellular processes driving senescence and SASP, and we provide a state-of-the-art of the anti-cancer strategies available so far that exploits the activation and/or blockade of senescence-based mechanisms.https://www.frontiersin.org/articles/10.3389/fcell.2022.1083743/fullsenescenceIL-1EGFRimmunotherapymoabsenotherapeutics |
| spellingShingle | Donatella Romaniello Donatella Romaniello Valerio Gelfo Valerio Gelfo Federica Pagano Michela Sgarzi Alessandra Morselli Cinzia Girone Daria Maria Filippini Daria Maria Filippini Gabriele D’Uva Gabriele D’Uva Gabriele D’Uva Mattia Lauriola Mattia Lauriola IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy Frontiers in Cell and Developmental Biology senescence IL-1 EGFR immunotherapy moab senotherapeutics |
| title | IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy |
| title_full | IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy |
| title_fullStr | IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy |
| title_full_unstemmed | IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy |
| title_short | IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy |
| title_sort | il 1 and senescence friends and foe of egfr neutralization and immunotherapy |
| topic | senescence IL-1 EGFR immunotherapy moab senotherapeutics |
| url | https://www.frontiersin.org/articles/10.3389/fcell.2022.1083743/full |
| work_keys_str_mv | AT donatellaromaniello il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT donatellaromaniello il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT valeriogelfo il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT valeriogelfo il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT federicapagano il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT michelasgarzi il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT alessandramorselli il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT cinziagirone il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT dariamariafilippini il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT dariamariafilippini il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT gabrieleduva il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT gabrieleduva il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT gabrieleduva il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT mattialauriola il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy AT mattialauriola il1andsenescencefriendsandfoeofegfrneutralizationandimmunotherapy |